II. Indications
- See ACE Inhibitor
III. Mechanism
- See ACE Inhibitor
- Non-sulfhydryl Angiotensin Converting Enzyme (ACE) inhibitor
- Trandolapril is a prodrug, converted to its active form Trandolaprilat in the liver via de-esterification
IV. Dosing: Adults
- Adequate 24 hour Blood Pressure control may require twice daily dosing
-
Hypertension
- Start 1 mg orally daily or divided twice daily
- Start 0.5 mg/day in renal dysfunction or comorbid Diuretic use
- Target 2 to 4 mg orally daily
- Start 1 mg orally daily or divided twice daily
-
Congestive Heart Failure (CHF) or post-Myocardial Infarction
- Start 0.5 to 1 mg orally daily
- Titrate to target 4 mg orally daily
- Maximum: 8 mg/day (but no benefit above 4 mg/day)
V. Supplied
- Available as generic scored tablet (1 mg) and unscored tablet (2 and 4 mg)
VI. Metabolism
- Excretion 66% hepatic and 33% renal
VII. Adverse Effects
- See ACE Inhibitor
VIII. Safety
- See ACE Inhibitor
- Pregnancy Category X
- Avoid in Lactation
IX. Resources
- Trandolapril (DailyMed)
X. References
- (2016) Presc Lett, Resource #321151, ACE Inhibitor Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 68-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
trandolapril (on 4/20/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TRANDOLAPRIL 1 MG TABLET | Generic | $0.21 each |
TRANDOLAPRIL 2 MG TABLET | Generic | $0.17 each |
TRANDOLAPRIL 4 MG TABLET | Generic | $0.24 each |
Ontology: trandolapril (C0076891)
Definition (NCI) | A non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, trandolapril is converted by de-esterification in the liver into its active form trandolaprilat. Trandolaprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II and results in vasodilation. Trandolaprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C052035 |
SnomedCT | 108562001, 386871006 |
English | 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid, trandolapril, trandolapril (medication), trolandapril, TRANDOLAPRIL, trandolapril [Chemical/Ingredient], Trandolapril, Trandolapril (product), Trandolapril (substance) |
Spanish | trandolaprilo, trandolapril (producto), trandolapril (sustancia), trandolapril |
Ontology: Mavik (C0721596)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C052035 |
English | Mavik, mavik, Gopten, Knoll brand of trandolapril, Abbott brand of trandolapril |